Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06422455 · ClinicalTrials.gov registry record · NA

Access to Genetic Testing in Underserved Patients With Cancer

A NA study of Malignant Solid Neoplasm and Breast Carcinoma, sponsored by University of Southern California.

Recruiting
Registry status
NA
Development phase
800
Enrollment target
2
Study locations

NCT06422455 is a NA study of Malignant Solid Neoplasm and Breast Carcinoma that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 800 participants, below the 1,136-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (30% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06422455, a NA study of Malignant Solid Neoplasm and Breast Carcinoma, is actively recruiting participants, sponsored by University of Southern California.

RECRUITING
Registry status
NA
Development phase
800 participants
Enrollment target
2
Study locations

Study Summary

This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider. Patients with cancer are increasingly recommended for genetic testing as standard of care. Multiple factors contribute to low usage of genetic testing but for many patients the lack of access to genetic counseling and testing is an important and flexible factor. Lack of access is especially relevant to racial/ethnic minority patients and those living in non-metropolitan rural settings who are frequently cared for at safety-net hospitals with limited genetics services. Alternative delivery models are necessary to improve rates of access to genetic testing in patients with cancer. Health information technology is under used by genetics providers. A patient-facing relational agent (PERLA) will provide pre-test genetics education in both English and Spanish across two clinical settings to facilitate more timely access to genetic testing. Using the PERLA intervention may help researchers learn different ways to provide education about genetic testing to patients with cancer compared to usual care.

Interventions

  • OTHER Best Practice
  • OTHER Educational Intervention
  • OTHER Electronic Health Record Review
  • OTHER Interview
  • OTHER Genetic Counseling

Study Locations (2)

California

  • USC / Norris Comprehensive Cancer Center - Los Angeles

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2023-10-24
Est. Completion 2028-10-24
Phase NA

Sponsor

University of Southern California

617 total trials

What the Registry Record Tells You About NCT06422455

The ClinicalTrials.gov registry entry for NCT06422455 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,136-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (30% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Best Practice is the first listed.

NCT06422455 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.

Frequently Asked Questions

What is clinical trial NCT06422455 about?

NCT06422455 is a clinical study titled "Access to Genetic Testing in Underserved Patients With Cancer". This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider. Patients with cancer are increasingly recommended for genetic testing as standard of care. Mu...

What is the current status of trial NCT06422455?

This trial is currently recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2023-10-24. Estimated completion is 2028-10-24.

What conditions does trial NCT06422455 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Breast Carcinoma, Metastatic Prostate Carcinoma, Ovarian Carcinoma, Triple-Negative Breast Carcinoma.

What interventions are being tested in trial NCT06422455?

The interventions under investigation include: Best Practice (OTHER), Educational Intervention (OTHER), Electronic Health Record Review (OTHER), Interview (OTHER), Genetic Counseling (OTHER).

Who is sponsoring clinical trial NCT06422455?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06422455 being conducted?

This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.